J Glaucoma:唐氏综合症患者的眼病发生发展

2018-11-28 MedSci MedSci原创

圣保罗大学RibeiroPreto医学院眼科的Faria-E-Sousa SJ近日在J Glaucoma杂志上发表了一篇文章,他们报告了一例患有唐氏综合症的成人发病特殊情况。

圣保罗大学RibeiroPreto医学院眼科的Faria-E-Sousa SJ近日在J Glaucoma杂志上发表了一篇文章,他们报告了一例患有唐氏综合症的成人发病特殊情况。

他们回顾了一名患有唐氏综合症的24岁患者的病历,该患者在角膜移植后发生左眼眶角膜病变。

患者在手术后2年,进行过手术的眼睛发展为慢性前房葡萄膜炎,导致进行性外周粘连、眼压周期变化、白内障,最终导致移植失败。

因此,他们认为,这项报告具有重要的意义,唐氏综合征成人发病意味着关于这种眼病的分类需要重新考虑,对检测21号染色体三体综合症患者青光眼的治疗方案也需要慎重制定。

原文出处:

Faria, E.S.S.J., et al., Adult-onset Buphthalmos in Down Syndrome. J Glaucoma, 2018.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1914200, encodeId=396f191420003, content=<a href='/topic/show?id=5ee629957f' target=_blank style='color:#2F92EE;'>#AUC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2995, encryptionId=5ee629957f, topicName=AUC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bfa6343, createdName=aliceclz, createdTime=Sun May 26 06:57:00 CST 2019, time=2019-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2030743, encodeId=c5882030e436e, content=<a href='/topic/show?id=71353e8964f' target=_blank style='color:#2F92EE;'>#发生发展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37896, encryptionId=71353e8964f, topicName=发生发展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=346311, createdName=wgsun, createdTime=Sat Feb 09 18:57:00 CST 2019, time=2019-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1450340, encodeId=bdb11450340dd, content=<a href='/topic/show?id=053a3999eea' target=_blank style='color:#2F92EE;'>#唐氏综合症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39997, encryptionId=053a3999eea, topicName=唐氏综合症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1eb25553762, createdName=huanbaofeng, createdTime=Fri Nov 30 12:57:00 CST 2018, time=2018-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1540517, encodeId=7588154051eb3, content=<a href='/topic/show?id=fbbce2786cc' target=_blank style='color:#2F92EE;'>#眼病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72786, encryptionId=fbbce2786cc, topicName=眼病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b85c13256921, createdName=pps20023, createdTime=Fri Nov 30 12:57:00 CST 2018, time=2018-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=353919, encodeId=25ba35391941, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0aa31415219, createdName=orangesking, createdTime=Wed Nov 28 22:50:53 CST 2018, time=2018-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=353914, encodeId=2326353914c5, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Wed Nov 28 22:40:22 CST 2018, time=2018-11-28, status=1, ipAttribution=)]
    2019-05-26 aliceclz
  2. [GetPortalCommentsPageByObjectIdResponse(id=1914200, encodeId=396f191420003, content=<a href='/topic/show?id=5ee629957f' target=_blank style='color:#2F92EE;'>#AUC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2995, encryptionId=5ee629957f, topicName=AUC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bfa6343, createdName=aliceclz, createdTime=Sun May 26 06:57:00 CST 2019, time=2019-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2030743, encodeId=c5882030e436e, content=<a href='/topic/show?id=71353e8964f' target=_blank style='color:#2F92EE;'>#发生发展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37896, encryptionId=71353e8964f, topicName=发生发展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=346311, createdName=wgsun, createdTime=Sat Feb 09 18:57:00 CST 2019, time=2019-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1450340, encodeId=bdb11450340dd, content=<a href='/topic/show?id=053a3999eea' target=_blank style='color:#2F92EE;'>#唐氏综合症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39997, encryptionId=053a3999eea, topicName=唐氏综合症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1eb25553762, createdName=huanbaofeng, createdTime=Fri Nov 30 12:57:00 CST 2018, time=2018-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1540517, encodeId=7588154051eb3, content=<a href='/topic/show?id=fbbce2786cc' target=_blank style='color:#2F92EE;'>#眼病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72786, encryptionId=fbbce2786cc, topicName=眼病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b85c13256921, createdName=pps20023, createdTime=Fri Nov 30 12:57:00 CST 2018, time=2018-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=353919, encodeId=25ba35391941, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0aa31415219, createdName=orangesking, createdTime=Wed Nov 28 22:50:53 CST 2018, time=2018-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=353914, encodeId=2326353914c5, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Wed Nov 28 22:40:22 CST 2018, time=2018-11-28, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1914200, encodeId=396f191420003, content=<a href='/topic/show?id=5ee629957f' target=_blank style='color:#2F92EE;'>#AUC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2995, encryptionId=5ee629957f, topicName=AUC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bfa6343, createdName=aliceclz, createdTime=Sun May 26 06:57:00 CST 2019, time=2019-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2030743, encodeId=c5882030e436e, content=<a href='/topic/show?id=71353e8964f' target=_blank style='color:#2F92EE;'>#发生发展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37896, encryptionId=71353e8964f, topicName=发生发展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=346311, createdName=wgsun, createdTime=Sat Feb 09 18:57:00 CST 2019, time=2019-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1450340, encodeId=bdb11450340dd, content=<a href='/topic/show?id=053a3999eea' target=_blank style='color:#2F92EE;'>#唐氏综合症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39997, encryptionId=053a3999eea, topicName=唐氏综合症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1eb25553762, createdName=huanbaofeng, createdTime=Fri Nov 30 12:57:00 CST 2018, time=2018-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1540517, encodeId=7588154051eb3, content=<a href='/topic/show?id=fbbce2786cc' target=_blank style='color:#2F92EE;'>#眼病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72786, encryptionId=fbbce2786cc, topicName=眼病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b85c13256921, createdName=pps20023, createdTime=Fri Nov 30 12:57:00 CST 2018, time=2018-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=353919, encodeId=25ba35391941, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0aa31415219, createdName=orangesking, createdTime=Wed Nov 28 22:50:53 CST 2018, time=2018-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=353914, encodeId=2326353914c5, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Wed Nov 28 22:40:22 CST 2018, time=2018-11-28, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1914200, encodeId=396f191420003, content=<a href='/topic/show?id=5ee629957f' target=_blank style='color:#2F92EE;'>#AUC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2995, encryptionId=5ee629957f, topicName=AUC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bfa6343, createdName=aliceclz, createdTime=Sun May 26 06:57:00 CST 2019, time=2019-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2030743, encodeId=c5882030e436e, content=<a href='/topic/show?id=71353e8964f' target=_blank style='color:#2F92EE;'>#发生发展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37896, encryptionId=71353e8964f, topicName=发生发展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=346311, createdName=wgsun, createdTime=Sat Feb 09 18:57:00 CST 2019, time=2019-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1450340, encodeId=bdb11450340dd, content=<a href='/topic/show?id=053a3999eea' target=_blank style='color:#2F92EE;'>#唐氏综合症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39997, encryptionId=053a3999eea, topicName=唐氏综合症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1eb25553762, createdName=huanbaofeng, createdTime=Fri Nov 30 12:57:00 CST 2018, time=2018-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1540517, encodeId=7588154051eb3, content=<a href='/topic/show?id=fbbce2786cc' target=_blank style='color:#2F92EE;'>#眼病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72786, encryptionId=fbbce2786cc, topicName=眼病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b85c13256921, createdName=pps20023, createdTime=Fri Nov 30 12:57:00 CST 2018, time=2018-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=353919, encodeId=25ba35391941, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0aa31415219, createdName=orangesking, createdTime=Wed Nov 28 22:50:53 CST 2018, time=2018-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=353914, encodeId=2326353914c5, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Wed Nov 28 22:40:22 CST 2018, time=2018-11-28, status=1, ipAttribution=)]
    2018-11-30 pps20023
  5. [GetPortalCommentsPageByObjectIdResponse(id=1914200, encodeId=396f191420003, content=<a href='/topic/show?id=5ee629957f' target=_blank style='color:#2F92EE;'>#AUC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2995, encryptionId=5ee629957f, topicName=AUC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bfa6343, createdName=aliceclz, createdTime=Sun May 26 06:57:00 CST 2019, time=2019-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2030743, encodeId=c5882030e436e, content=<a href='/topic/show?id=71353e8964f' target=_blank style='color:#2F92EE;'>#发生发展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37896, encryptionId=71353e8964f, topicName=发生发展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=346311, createdName=wgsun, createdTime=Sat Feb 09 18:57:00 CST 2019, time=2019-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1450340, encodeId=bdb11450340dd, content=<a href='/topic/show?id=053a3999eea' target=_blank style='color:#2F92EE;'>#唐氏综合症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39997, encryptionId=053a3999eea, topicName=唐氏综合症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1eb25553762, createdName=huanbaofeng, createdTime=Fri Nov 30 12:57:00 CST 2018, time=2018-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1540517, encodeId=7588154051eb3, content=<a href='/topic/show?id=fbbce2786cc' target=_blank style='color:#2F92EE;'>#眼病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72786, encryptionId=fbbce2786cc, topicName=眼病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b85c13256921, createdName=pps20023, createdTime=Fri Nov 30 12:57:00 CST 2018, time=2018-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=353919, encodeId=25ba35391941, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0aa31415219, createdName=orangesking, createdTime=Wed Nov 28 22:50:53 CST 2018, time=2018-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=353914, encodeId=2326353914c5, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Wed Nov 28 22:40:22 CST 2018, time=2018-11-28, status=1, ipAttribution=)]
    2018-11-28 orangesking

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1914200, encodeId=396f191420003, content=<a href='/topic/show?id=5ee629957f' target=_blank style='color:#2F92EE;'>#AUC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2995, encryptionId=5ee629957f, topicName=AUC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bfa6343, createdName=aliceclz, createdTime=Sun May 26 06:57:00 CST 2019, time=2019-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2030743, encodeId=c5882030e436e, content=<a href='/topic/show?id=71353e8964f' target=_blank style='color:#2F92EE;'>#发生发展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37896, encryptionId=71353e8964f, topicName=发生发展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=346311, createdName=wgsun, createdTime=Sat Feb 09 18:57:00 CST 2019, time=2019-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1450340, encodeId=bdb11450340dd, content=<a href='/topic/show?id=053a3999eea' target=_blank style='color:#2F92EE;'>#唐氏综合症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39997, encryptionId=053a3999eea, topicName=唐氏综合症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1eb25553762, createdName=huanbaofeng, createdTime=Fri Nov 30 12:57:00 CST 2018, time=2018-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1540517, encodeId=7588154051eb3, content=<a href='/topic/show?id=fbbce2786cc' target=_blank style='color:#2F92EE;'>#眼病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72786, encryptionId=fbbce2786cc, topicName=眼病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b85c13256921, createdName=pps20023, createdTime=Fri Nov 30 12:57:00 CST 2018, time=2018-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=353919, encodeId=25ba35391941, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0aa31415219, createdName=orangesking, createdTime=Wed Nov 28 22:50:53 CST 2018, time=2018-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=353914, encodeId=2326353914c5, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Wed Nov 28 22:40:22 CST 2018, time=2018-11-28, status=1, ipAttribution=)]
    2018-11-28 医者仁心5538

    学习了

    0

相关资讯

Exp Clin Transplant:供体角膜对穿透性角膜移植手术结果的影响

土耳其安卡拉培训与研究医院的眼科的Singar-Ozdemir E近日在Exp Clin Transplant发表了一篇文章,在这项研究中,他们比较了分别使用国产和进口供体角膜进行穿透性角膜移植术的手术效果。

Cornea:激光原位角膜磨镶术后眼睛中央上皮厚度与中央角膜厚度的关系

俄罗斯圣彼得堡军事医学科学院眼科的Maltsev DS近日在Cornea发表了一项工作,他们研究了健康人中央上皮厚度(CET)与中央角膜厚度(CCT)之间的关系,并评估其在激光原位角膜磨削术(LASIK)后的变化。

北京协和医院:近视手术余留角膜“变废为宝”守光明

记者近日从北京协和医院获悉,该院率先将激光近视手术中切下取出的余留角膜材料“变废为宝”,用于角膜病患者的角膜移植,三年多来已完成几十例手术,且目前未发生排异反应,为拓宽角膜移植供体来源、缓解角膜供体不足提供了新思路。据了解,因缺乏角膜材料,很多角膜溃疡患者以往只能采用很薄的生物羊膜堵住创面。自2014年起,北京协和医院眼科教授李莹团队率先将全飞秒激光近视手术(SMILE)取出的角膜材料用于角膜移植

J Cell Mol Med:角膜缘细胞是成体间充质干细胞的有效来源

深圳大学眼视光学院深圳眼科医院的Guo P近日在J Cell Mol Med发表了一篇文章,他们论述了角膜缘细胞是成体间充质干细胞的有效来源。

研究人员创建了第一个 3D 打印的角膜来消除失明

纽卡斯尔大学的研究人员已经宣布,他们已经设法 3D 打印角膜,即人眼最外面的部分。目前,全球有 1000 万人需要手术来预防沙眼等疾病引起的角膜失明。最重要的是,由于事故或疾病导致的角膜疤痕让近 500 万人完全失明,现在,这种生产角膜的高科技方法可以结束这一切。

Lab Chip:微型人角膜上皮芯片成功构建

美国得克萨斯理工大学机械工程系的Bennet D和得克萨斯理工大学健康科学中心眼科的Reid T近日在Lab Chip发表了一篇文章。在这项工作中,研究者构建了一个多孔膜嵌入式微流体平台,它可以将芯片分成顶端和基底端。